| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
δ-Tocotrienol targets multiple pathways involved in cell proliferation, survival, and inflammation. It is an apoptosis inducer and an NF-κB inhibitor. It has anti-angiogenic activity, reducing vascular endothelial growth factor (VEGF)-stimulated tube formation. It also exhibits radioprotective and bone density conservation effects.
|
|---|---|
| ln Vitro |
In vitro, δ-tocotrienol inhibits the proliferation of various cancer cell lines, including colorectal carcinoma and breast cancer cells. It induces apoptosis and inhibits cell invasion. It is a potent antioxidant, reducing cell death induced by oxidative stress.
|
| ln Vivo |
In vivo, δ-tocotrienol has shown promising anticancer properties in preclinical models. It inhibits the growth of tumors and has been studied for its potential in cancer prevention and therapy. Its anti-inflammatory and antioxidant effects also suggest benefits for other chronic diseases.
|
| Enzyme Assay |
Non-cellular assays for δ-tocotrienol typically involve measuring its antioxidant activity using DPPH or ABTS radical scavenging assays. Its anti-inflammatory activity can be assessed by measuring its ability to inhibit NF-κB activation or the production of inflammatory mediators in cell-free systems.
|
| Cell Assay |
Cellular assays for δ-tocotrienol are conducted using various cancer cell lines, such as colorectal carcinoma cells, to assess its antiproliferative and pro-apoptotic effects. Cells are treated with the compound, and cell viability, apoptosis markers, and signaling pathways (e.g., NF-κB) are analyzed.
|
| Animal Protocol |
In vivo animal experiments for δ-tocotrienol typically involve mouse models of cancer, such as xenografts. The compound is administered orally or via injection, and tumor growth, angiogenesis, and survival are assessed. Its effects on bone density and radiation protection may also be studied.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of δ-tocotrienol are related to its lipophilic nature. It is absorbed from the gastrointestinal tract and distributed to various tissues. It has a relatively short half-life compared to tocopherols. Its metabolism and tissue distribution are areas of ongoing research.
|
| Toxicity/Toxicokinetics |
Toxicological data for δ-tocotrienol indicate that it is safe and well-tolerated. As a natural form of vitamin E, it has a favorable safety profile. No significant toxicity has been reported at typical doses.
|
| Additional Infomation |
δ-Tocotrienol is a tocotrienol with the structure chroman-6-ol, substituted with methyl groups at positions 2 and 8, and a farnesyl chain attached at position 2. It is a plant metabolite with various activities including NF-κB inhibitor, antitumor agent, apoptosis inducer, Saccharomyces cerevisiae metabolite, radiation protectant, anti-inflammatory agent, and bone mineral density maintainer. It is both a tocotrienol and vitamin E. δ-Tocotrienol has been reported to exist in Garcinia multiflora, Bixa orellana, and other organisms with relevant data. δ-Tocotrienol is the δ-form of tocotrienols, a member of the vitamin E family, and possesses potential antitumor activity. After administration, δ-Tocotrienol accumulates in cancer cells, and its anticancer activity may be achieved in part through downregulation and/or degradation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, cell cycle arrest, and induction of caspase-mediated apoptosis. Furthermore, this drug may partially inhibit angiogenesis by blocking vascular endothelial growth factor receptor (VEGFR) and suppressing tumor cell-induced angiogenesis. In summary, these effects may lead to the inhibition of tumor cell growth. The presence of three double bonds on the farnesylisoprene side chain of tocotrienol (absent in tocopherol) may be one reason for its anticancer activity.
δ-Tocotrienol is a promising natural compound for cancer prevention and therapy. It exhibits superior anticancer activity compared to other vitamin E isoforms. It is a valuable research tool for studying the mechanisms of cancer, inflammation, and oxidative stress. |
| Molecular Formula |
C27H40O2
|
|---|---|
| Molecular Weight |
396.61
|
| Exact Mass |
396.302
|
| CAS # |
25612-59-3
|
| PubChem CID |
5282350
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
517.3±39.0 °C at 760 mmHg
|
| Flash Point |
212.8±21.3 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.524
|
| LogP |
9.84
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
29
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2C(C([H])([H])[H])=C([H])C(=C([H])C=2C([H])([H])C([H])([H])[C@@]1(C([H])([H])[H])C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])O[H]
|
| InChi Key |
ODADKLYLWWCHNB-LDYBVBFYSA-N
|
| InChi Code |
InChI=1S/C27H40O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-16-27(6)17-15-24-19-25(28)18-23(5)26(24)29-27/h10,12,14,18-19,28H,7-9,11,13,15-17H2,1-6H3/b21-12+,22-14+/t27-/m1/s1
|
| Chemical Name |
(2R)-2,8-dimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (252.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.30 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.30 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5214 mL | 12.6068 mL | 25.2137 mL | |
| 5 mM | 0.5043 mL | 2.5214 mL | 5.0427 mL | |
| 10 mM | 0.2521 mL | 1.2607 mL | 2.5214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
